Li, J., Zhan, X., Shao, M., Zeng, R., Li, J., Zhu, H., Feng, A., Yang, Z., Jing, W. (2025). Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study. Scientific Reports. https://doi.org/10.1038/s41598-025-03422-9